

HRN:	
ID Card:	

OncoCUP Dx - Order Form

Biochemistry							
General:	Creatinine		ASAT Total Bilirubin	\boxtimes	ALAT		
Tumor Markers:	AFP CA 19.9 CEA NSE PSA Free		β-hCG CA 72.4 CYFRA 21-1 ProGRP SCC		CA 15.3 CA 125 HE4 PSA Total S100		
Anamnesis							
Personal Data Gender: Race:	Male African Unknown		Female Hispanic/Latino		Unknown Other		
Age (years):							
Comorbidities Ascites: Benign Prostatic Hyperplasia: Cholestasis: Chronic Liver Disease: Jaundice: Metrorrhagia: Pancreatitis: Pemphigus/Psoriasis: Pericardial/Pleural Effusions: Prostatitis: Renal Failure: Lifestyle	Yes		No N		Unknown		
Smoking:	Never Unknown		Currently		Past		
Order Information							
Ordered by:			Signature:				
Order Date:							
Disclaimer							

According to Annex VII of Medical Device Directive 93/42/EEC, Class I, Rule 12, OncoCUP Dx is a non-invasive blood test useful to suggest a possible diagnosis in patients with suspected malignancy, reduce inappropriate diagnostic tests, days of hospitalization, as well as morbidity. It is specially designed for patients with paraneoplastic syndrome and/or suspicion of advanced neoplasia, which the clinician can focus on tests that confirm the diagnosis, avoiding others to look for chronic or other benign diseases, as well as patients with cancer found in one or more metastatic sites but not the primary site.

OncoCUP Dx is based in a panel consisting of 15 serum Tumor Markers (AFP, β -hCG, CA 15.3, CA 19.9, CA 72.4, CA 125, CEA, CYFRA, HE4, NSE, ProGRP, PSA, fPSA, SCC and S100), as well as clinical data to obtain the best performance (Sensitivity of 82.4% and Specificity of 98.1%), by reducing the number of false positives generated by benign comorbidities and other well-known causes.

Bioprognos SL

Benet Mateu, 40 - 08034 Barcelona (Spain)

Email: info@bioprognos.com Website: www.bioprognos.com

